TherapeuticsMD (NASDAQ:TXMD) Shares Down 0.9% – Should You Sell?

TherapeuticsMD, Inc. (NASDAQ:TXMD)’s stock price fell 0.9% on Tuesday . The stock traded as low as $2.15 and last traded at $2.22. 39,779 shares changed hands during trading, an increase of 20% from the average session volume of 33,174 shares. The stock had previously closed at $2.24.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded TherapeuticsMD from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, January 12th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the company has an average rating of “Hold”.

TherapeuticsMD Price Performance

The stock has a 50-day moving average price of $2.19 and a 200-day moving average price of $1.62. The firm has a market capitalization of $25.81 million, a PE ratio of -223.00 and a beta of 0.51.

Institutional Trading of TherapeuticsMD

A number of hedge funds have recently made changes to their positions in TXMD. Citadel Advisors LLC raised its holdings in TherapeuticsMD by 125.5% in the third quarter. Citadel Advisors LLC now owns 34,273 shares of the company’s stock valued at $36,000 after acquiring an additional 19,073 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of TherapeuticsMD by 171.8% in the 4th quarter. Renaissance Technologies LLC now owns 96,500 shares of the company’s stock worth $157,000 after purchasing an additional 61,000 shares during the last quarter. Finally, Tejara Capital Ltd raised its stake in shares of TherapeuticsMD by 1.9% in the 4th quarter. Tejara Capital Ltd now owns 350,852 shares of the company’s stock valued at $572,000 after purchasing an additional 6,649 shares in the last quarter. Institutional investors and hedge funds own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.